Published in J Clin Pharmacol on November 01, 2002
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2008) 1.51
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol (2005) 1.49
Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter. Clin Cancer Res (2012) 1.41
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol (2008) 1.06
Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer (2010) 1.04
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res (2010) 1.04
Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv (2009) 1.02
Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev (2006) 1.01
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer (2007) 0.97
Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol (2011) 0.97
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clin Oral Investig (2011) 0.95
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Mol Ther (2013) 0.91
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer (2010) 0.91
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clin Pharmacol (2008) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer (2012) 0.89
Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med (2014) 0.88
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Side effects of bone-targeted therapies in advanced breast cancer. Breast Care (Basel) (2014) 0.86
A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair (2010) 0.86
Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clin Exp Metastasis (2015) 0.86
Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea. Otol Neurotol (2015) 0.85
Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound. PLoS One (2015) 0.85
Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Br J Cancer (2014) 0.84
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. BMC Cancer (2009) 0.83
Closure of an open wound associated with bisphosphonate-related osteonecrosis of the jaw in a breast cancer patient. Open Dent J (2011) 0.82
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS One (2013) 0.81
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int (2012) 0.81
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer (2007) 0.80
Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol (2015) 0.80
A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells. J Bone Miner Res (2015) 0.79
Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique. Cancer Biol Ther (2014) 0.79
A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. Small GTPases (2015) 0.79
CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther (2011) 0.79
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. Int J Mol Sci (2016) 0.78
A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei Med J (2007) 0.78
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Sci Rep (2015) 0.78
Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study. BMC Musculoskelet Disord (2014) 0.77
An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. Springerplus (2016) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging (2008) 0.77
Detecting early biomechanical effects of zoledronic Acid on femurs of osteoporotic female rats. J Osteoporos (2012) 0.77
A rare case of zolendronate infusion complication leading to glaucoma filtration surgery. Clin Ophthalmol (2011) 0.76
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report. J Med Case Rep (2011) 0.75
Effects of zoledronic acid on physiologic bone remodeling of condylar part of TMJ: a radiologic and histomorphometric examination in rabbits. ScientificWorldJournal (2014) 0.75
Current approaches to bone-targeted therapy in genitourinary malignancies. Ther Adv Urol (2012) 0.75
Systemic and local zoledronic acid treatment with hydroxyapatite bone graft: A histological and histomorphometric experimental study. Exp Ther Med (2016) 0.75
Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.75
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab (2007) 0.75
Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int (2009) 0.75
Nitrogen-containing bisphosphonates modulate the antigenic profile and inhibit the maturation and biomineralization potential of osteoblast-like cells. Clin Oral Investig (2014) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst (2012) 2.78
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 2.25
Clinical pharmacokinetics of imatinib. Clin Pharmacokinet (2005) 2.08
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer (2003) 2.04
Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn (2008) 1.97
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol (2008) 1.78
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 1.68
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol (2004) 1.37
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One (2011) 1.34
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood (2009) 1.32
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res (2010) 1.30
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers. Psychooncology (2012) 1.29
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol (2006) 1.24
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos (2008) 1.19
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol (2003) 1.16
Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal (2002) 1.16
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging (2003) 1.15
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos (2009) 1.15
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.14
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest (2002) 1.13
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol (2005) 1.11
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs (2004) 1.11
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol (2009) 1.11
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer (2006) 1.05
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant (2003) 1.04
Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy (2009) 1.03
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs (2012) 1.03
Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol (2002) 1.03
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol (2008) 1.03
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol (2005) 1.02
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol (2004) 1.01
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res (2009) 1.01
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res (2006) 1.00
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation (2003) 1.00
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.00
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood (2005) 0.99
Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol (2010) 0.98
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol (2009) 0.98
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol (2008) 0.98
Inhibitory Effect of a γ-Tocopherol-Rich Mixture of Tocopherols on the Formation and Growth of LNCaP Prostate Tumors in Immunodeficient Mice. Cancers (Basel) (2011) 0.97
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm (2006) 0.96
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate (2005) 0.95
Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs (2005) 0.95
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol (2009) 0.94
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2005) 0.93
Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol (2008) 0.93
Management of bone disease in multiple myeloma. Expert Rev Hematol (2014) 0.93
Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs (2002) 0.92
A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Clin Pharmacokinet (2008) 0.92
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer (2010) 0.92
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs (2011) 0.92
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol (2013) 0.92
Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol (2010) 0.92
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther (2005) 0.92
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol (2009) 0.91
Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol (2014) 0.91
Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program (2000) 0.91
Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol (2009) 0.91
Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res (2011) 0.90
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol (2009) 0.90
Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol (2004) 0.89
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clin Pharmacol (2008) 0.89
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol (2011) 0.89
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol (2013) 0.89
Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res (2014) 0.88
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2013) 0.87
gp120-independent HIV infection of cells derived from the female reproductive tract, brain, and colon. J Acquir Immune Defic Syndr (2006) 0.87
Conceptualization of disease timeline predicts posttreatment distress in breast cancer patients. Health Psychol (2004) 0.87
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol (2004) 0.86
A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit (2009) 0.86
The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J (2012) 0.86
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.86
Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit (2012) 0.85
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicol Sci (2012) 0.85
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets (2011) 0.85
Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm (2006) 0.85